Literature DB >> 25205447

Marine-Lenhart syndrome.

Mark Henry Joven1, Robert J Anderson.   

Abstract

Mesh：

Year:  2014        PMID： 25205447     DOI： 10.1007/s12020-014-0412-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

Review 1.  Thyroid cancer and Graves' disease.

Authors:  E L Mazzaferri
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

2.  Graves' disease with functioning nodules (Marine-Lenhart syndrome).

Authors:  N D Charkes
Journal:  J Nucl Med       Date:  1972-12       Impact factor: 10.057

3.  Thyroid nodules in Graves' disease: classification, characterization, and response to treatment.

Authors:  N E Carnell; W A Valente
Journal:  Thyroid       Date:  1998-07       Impact factor: 6.568
  3 in total
  5 in total

1.  Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan.

Authors:  Hirosuke Danno; Eijun Nishihara; Kazuyoshi Kousaka; Tomohiko Nakamura; Toshihiko Kasahara; Takumi Kudo; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Akira Miyauchi
Journal:  Eur Thyroid J       Date:  2020-09-30

2.  Marine-Lenhart Syndrome: Case Report, Diagnosis, and Management.

Authors:  Danielle Neuman; Russ Kuker; Francesco Vendrame
Journal:  Case Rep Endocrinol       Date:  2018-10-24

3.  Recurrent Goiter Presented with Marine-Lenhart Syndrome 27 Years After Initial Surgery.

Authors:  Emin Gurleyik
Journal:  Cureus       Date:  2019-09-26

4.  Graves disease following radioiodine therapy for toxic adenoma: Clinical case report.

Authors:  Guohua Shen; Futao Cui; Rui Huang; Anren Kuang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

5.  Type 2 Marine-Lenhart Syndrome: An Uncommon Cause of Thyrotoxicosis.

Authors:  Carlos Alfonso Builes Barrera; Pablo Alberto Castaño; Paula Herrera Revollo; Marcel Eduardo Pérez Paternina; Luis Antonio Rodriguez Arrieta
Journal:  Cureus       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.